ICEおよび電気自動車用アクチュエータ市場：製品タイプ別（ブレーキ、スロットル、ターボ、その他）、用途別（エンジン、ボディ制御・外装、内装）、オンハイウェイ車・オフハイウェイ車、アクチュエーション、動作、地域別 - 2030年までの世界予測

Automotive Actuators Market for ICE and Electric Vehicle by Product Type (Brake, Throttle, Turbo, and Others), Application (Engine, Body Control & Exterior, Interior), On- and Off-highway Vehicles, Actuation, Motion and Region - Global Forecast to 2030

自動車用アクチュエータ市場は、2023年の209億米ドルから2030年には293億米ドルに成長すると予測され、予測期間中の年平均成長率は4.9%である。先進国における高級車やSUVの販売台数の増加、運転支援機能を搭載... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年11月9日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	345	411	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

自動車用アクチュエータ市場は、2023年の209億米ドルから2030年には293億米ドルに成長すると予測され、予測期間中の年平均成長率は4.9%である。
先進国における高級車やSUVの販売台数の増加、運転支援機能を搭載した自動車の生産台数の増加、Global NCAPの評価による安全性の重視の高まりにより、OEMは様々な用途向けの自動車用アクチュエータの開発に注力している。
"ブレーキアクチュエータが自動車用アクチュエータ市場を支配している"
ブレーキアクチュエータ分野は、あらゆるタイプの車両セグメントに装着が義務付けられていることと、他のタイプのアクチュエータに比べてコストが高いことから、自動車用アクチュエータ市場を支配すると予測されている。ブレーキアクチュエータの数は、乗用車では通常4個であり、小型商用車では車輪1つにつき1個である。乗用車の安全性と利便性を向上させることは、世界中の政府機関やOEMが最も重視していることである。このため、各地で厳しい安全規制が実施されている。このため、ほとんどの国でアンチロック・ブレーキ・システム（ABS）、電子制御制動力配分システム（EBD）、ブレーキ・アシストなどの先進ブレーキ技術が義務化されつつある。
さらに、欧州連合（EU）は、ADAS技術の一部である誤作動を防止するため、乗用車とLCVに緊急ブレーキシステムの搭載を義務付けた。さらに、ブレーキ・バイ・ワイヤ・システムや回生ブレーキ・システムなど、ブレーキ技術の進歩も進んでおり、ブレーキ・システムの性能や安全性、自動車の燃費が向上している。これらの要因、規制、いくつかの追加安全機能は、今後数年間の効率的なブレーキアクチュエーターセグメントの成長に起因している。
一方、大型商用車のブレーキアクチュエータの平均数ははるかに多く、コストも高い。大型商用車のエアディスクブレーキシステムは、その優れた制動能力により、ますます人気が高まっている。このため、メーカー各社は、エアディスクブレーキやドラムブレーキ用のブレーキアクチュエータのように、あらゆるサイズと性能レベルのブレーキアクチュエータで革新的なソリューションを提供するようになり、自動車用アクチュエータ市場を牽引することになるだろう。

「乗用車は、自動車用アクチュエータ市場において最も大きく、また最も急速に成長しているオンハイウェイ車セグメントである。
乗用車セグメントは、自動車用アクチュエータ市場において最も有望かつ急成長する市場と推定される。この成長の主な要因は、乗用車セグメントのシェアが最も高く、自動車生産台数全体の70％以上を占めていることである。機械部品と電子部品の採用が増加していることが、自動車用アクチュエータ市場を後押ししている。乗用車には、スロットルボディー、エンジン冷却バルブ、ブレーキ、エアコン、パワーウィンドウなど、すべてのカテゴリーで取り付けが義務付けられている標準アクチュエーターがいくつか装備されている。さらに、エンジンのダウンサイジングやGDIエンジンへの移行が、ターボや排気ガス再循環（EGR）システムアクチュエータの需要を促すだろう。
さらに、欧州、北米、日本や韓国などのアジア諸国の先進国は、廃棄所得が高く、ミッドレンジ、プレミアム、フルサイズのSUVに対する需要が旺盛であるため、快適性と豪華な機能に傾斜している。このため、電動シート、マルチゾーン・エアコン、2列目・3列目エアコン、電動テールゲート、ドアロック、アクティブ・グリル・シャッター、パッシブ・アクティブ・キャビン・ベンチレーションといった高度な機能に対する需要が高まり、乗用車セグメントでは、これらの用途に自動車用アクチュエータを採用する動きが強まるだろう。さらに、欧州新車アセスメント・プログラム（Euro NCAP）やビジョン・ゼロ（Vision Zero）といった政府の取り組みにより、欧州や中国、インドといったアジアの発展途上国のOEMは、欧州の基準に従って高度な安全機能を搭載することを余儀なくされている。

"アジア太平洋地域は自動車用アクチュエータ市場で最も顕著な地域である"
アジア太平洋地域は、自動車用アクチュエータ市場で最も著名な地域であり、予測期間中に最も速いCAGRで成長すると予想される。アジア太平洋地域は、近年自動車生産の拠点として台頭しており、2022年には55%以上と、世界の自動車生産において最大のシェアを占めている。この地域の自動車生産台数は、自動車用アクチュエータ市場に大きな成長機会をもたらしている。また、中国、インド、日本などの国々では、プレミアムカーや高級車への需要が高まり、電気自動車の販売が増加していることも、自動車用アクチュエーターの成長を後押ししている。また、車内の快適性に優れた高級大型車は、パワーシートアクチュエーター、パワーウィンドウアクチュエーター、ブレーキアクチュエーター、ステアリングコラム調整用アクチュエーターなどの自動車用アクチュエーターの需要に拍車をかけている。アジア太平洋地域では、他の地域に比べて乗用車のシェアが大きいため、ブレーキアクチュエータが最大の市場シェアを占めている。
一方、テレスコピックアクチュエーターは、ステアリングシステム、ヘッドライト作動システム、トラックリッド作動システムなど、自動車の様々なシステムに応用されているため、最も高いCAGRで成長すると予想される。また、ステアリングシステム、ヘッドライト作動システム、トラックリッド作動システムなど、自動車の様々なシステムに応用されているため、小型商用車や大型商用車の販売増加がテレスコピックアクチュエーター市場を最も高いCAGRで牽引している。アジア太平洋地域には、Robert Bosch、HELLA GmbH、Brakes India Pvt. Ltd.など、アクチュエーターの世界的メーカーの多くが進出している。

自動車用アクチュエータ市場における主要参入企業のプロファイルの内訳：
企業別アクチュエーターメーカー30%、ティア2サプライヤー50%、OEM20
役職別Cレベル幹部：60%、役員：15%、その他：25
地域別北米：10％、アジア太平洋：75％、欧州：10％、RoW：5

自動車用アクチュエーター市場は、世界的なプレーヤーが支配的であり、いくつかの地域的なプレーヤーで構成されている。自動車用アクチュエーター市場の主要企業は、Robert Bosch（ドイツ）、HELLA GmbH & Co.KGaA（ドイツ）、ジョンソン・エレクトリック（中国）、デンソー（日本）、コンチネンタルAG（ドイツ）である。

レポート購入の主なメリット
本レポートは、自動車用アクチュエータ市場全体とサブセグメントにおける収益数の最も近い近似値に関する情報を提供し、市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するための洞察を得るのに役立ちます。また、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供するのにも役立ちます。
本レポートは、以下のポイントに関する洞察を提供します：
- 自動車用アクチュエータ市場の成長に影響を与える主な促進要因（先進機能搭載車への需要増加、プレミアム車への需要増加）、阻害要因（ディーゼル乗用車のシェア低下）、機会（電動アクチュエータの採用増加）、課題（軽量化とコスト削減）の分析。
- 製品開発/イノベーション：自動車用アクチュエータ市場における今後の技術や新製品・新サービスの発表に関する詳細な洞察。
- 市場開発：包括的な市場情報 - 当レポートでは、さまざまな地域における認証およびブランド保護市場を分析しています。
- 市場の多様化：自動車用アクチュエータ市場における新製品・サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：Robert Bosch社（ドイツ）、HELLA GmbH & Co.KGaA（ドイツ）、JOHNSON Electric（中国）、株式会社デンソー（日本）、Continental AG（ドイツ）など、自動車用アクチュエータ市場における主要企業の市場シェア、成長戦略、サービス内容を詳細に評価します。

ページTOPに戻る

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 INCLUSIONS & EXCLUSIONS 45
1.4 MARKET SCOPE 45
1.4.1 MARKETS COVERED 45
1.4.2 REGIONS COVERED 46
1.4.3 YEARS CONSIDERED 46
1.4.4 CURRENCY CONSIDERED 46
1.5 RESEARCH LIMITATIONS 47
1.6 STAKEHOLDERS 47
1.7 SUMMARY OF CHANGES 48
1.8 RECESSION IMPACT: VACCINES MARKET 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.2 RESEARCH APPROACH 49
FIGURE 1 RESEARCH DESIGN 49
2.2.1 SECONDARY DATA 50
2.2.2 PRIMARY DATA 51
FIGURE 2 BREAKDOWN OF PRIMARIES 51
2.2.2.1 Primary insights 52
FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS 52
2.3 MARKET SIZE ESTIMATION 53
FIGURE 4 MARKET SIZE ESTIMATION: VACCINES MARKET, 2022 53
FIGURE 5 TOTAL REVENUE: VACCINES MARKET 54
FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022 54
2.3.1 SEGMENTAL ASSESSMENT 55
FIGURE 7 TOP-DOWN APPROACH 55
2.4 GROWTH RATE ASSUMPTIONS 57
FIGURE 8 CAGR PROJECTION: VACCINES MARKET 57
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 58
2.5 STUDY ASSUMPTIONS 58
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION 59
FIGURE 10 DATA TRIANGULATION METHODOLOGY 59
2.7 RISK ASSESSMENT 60

2.8 IMPACT OF RECESSION IN VACCINES MARKET 60
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 61
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 61
3 EXECUTIVE SUMMARY 62
FIGURE 11 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 62
FIGURE 12 VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 63
FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION) 64
FIGURE 14 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION) 65
FIGURE 15 VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 65
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET 66
4 PREMIUM INSIGHTS 68
4.1 VACCINES MARKET OVERVIEW 68
FIGURE 17 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 68
4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY AND COUNTRY, 2022 69
FIGURE 18 M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022 69
4.3 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 70
FIGURE 19 M-RNA VACCINES TO DOMINATE MARKET IN 2028 70
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET 70
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET 71
TABLE 4 IMPACT ANALYSIS: VACCINES MARKET 72
5.2.1 DRIVERS 72
5.2.1.1 Strong emphasis on launch of novel vaccines 72
5.2.1.2 Rising prevalence of infectious diseases 73
FIGURE 22 INCIDENCE OF TUBERCULOSIS IN US, 2017–2021 74
5.2.1.3 Increasing number of immunization programs 74
5.2.1.4 Advancements in vaccine technology 75
5.2.1.5 Robust government support and funding for vaccine development 75
TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 High cost of vaccine development 76

5.2.3 OPPORTUNITIES 77
5.2.3.1 Increased focus on therapeutic vaccines 77
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 77
5.2.4 CHALLENGES 78
5.2.4.1 Stringent regulatory processes 78
5.2.4.2 Frequent product recalls 78
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
FIGURE 23 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS 79
5.4 PRICING ANALYSIS 79
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 79
TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES 79
TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES 81
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 82
TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES 82
TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES 82
TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES 83
TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES 83
TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES 84
TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES 84
5.4.3 AVERAGE SELLING PRICE TREND 85
5.5 TECHNOLOGY ANALYSIS 85
5.6 VALUE CHAIN ANALYSIS 85
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 86
5.7 PIPELINE ANALYSIS 87
FIGURE 25 CLINICAL TRIALS IN VACCINES MARKET 87
FIGURE 26 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION 87
TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS 88
5.7.1 KEY PIPELINE PRODUCTS 91
TABLE 15 KEY PIPELINE VACCINES: GSK PL 91
TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC. 91
TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC. 91
TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A. 91
5.8 ECOSYSTEM MARKET/MAP 92
FIGURE 27 ECOSYSTEM MARKET/MAP 92
TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET 92
5.9 REGULATORY ANALYSIS 93
5.9.1 REGULATORY LANDSCAPE FOR VACCINES 93
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
5.10 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 26 PORTER’S FIVE FORCES ANALYSIS 98
5.10.1 THREAT OF NEW ENTRANTS 99
5.10.2 THREAT OF SUBSTITUTES 99
5.10.3 BARGAINING POWER OF SUPPLIERS 99
5.10.4 BARGAINING POWER OF BUYERS 99
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 99
5.11 PATENT ANALYSIS 100
FIGURE 28 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023 100
TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET 100
5.12 KEY CONFERENCES & EVENTS 101
TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024 101
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 102
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 102
5.13.2 KEY BUYING CRITERIA 103
FIGURE 30 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET 103
6 VACCINES MARKET, BY TECHNOLOGY 104
6.1 INTRODUCTION 105
TABLE 29 VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 105
6.2 CONJUGATE VACCINES 105
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET 105
TABLE 30 VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021–2028 (USD BILLION) 106
TABLE 31 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 32 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 33 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108
TABLE 34 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108

6.3 RECOMBINANT VACCINES 108
6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET 108
TABLE 35 EXAMPLES OF RECOMBINANT VACCINES 109
TABLE 36 VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2021–2028 (USD BILLION) 110
TABLE 37 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 38 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 39 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 40 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 112
6.4 INACTIVATED & SUBUNIT VACCINES 112
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET 112
TABLE 41 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 113
TABLE 42 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION, 2021–2028 (USD BILLION) 114
TABLE 43 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 114
TABLE 44 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 45 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 46 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 116
6.5 LIVE ATTENUATED VACCINES 116
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET 116
TABLE 47 EXAMPLES OF LIVE ATTENUATED VACCINES 117
TABLE 48 VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021–2028 (USD BILLION) 117
TABLE 49 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 50 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 51 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
TABLE 52 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
6.6 TOXOID VACCINES 119
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET 119
TABLE 53 EXAMPLES OF TOXOID VACCINES 120
TABLE 54 VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021–2028 (USD BILLION) 120
TABLE 55 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 56 EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
TABLE 58 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
6.7 VIRAL VECTOR VACCINES 123
6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 123
TABLE 59 VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION, 2021–2028 (USD BILLION) 123
TABLE 60 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 61 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 62 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
TABLE 63 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
6.8 M-RNA VACCINES 126
6.8.1 INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET 126
TABLE 64 VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021–2028 (USD BILLION) 127
TABLE 65 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 127
TABLE 66 EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 67 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 68 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 129
6.9 OTHER VACCINES 129
TABLE 69 VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021–2028 (USD BILLION) 130
TABLE 70 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 130
TABLE 71 EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 72 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 73 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 132

7 VACCINES MARKET, BY TYPE 133
7.1 INTRODUCTION 134
TABLE 74 VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 134
7.2 MONOVALENT VACCINES 134
7.2.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 134
TABLE 75 EXAMPLES OF MONOVALENT VACCINES 135
TABLE 76 VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 136
TABLE 77 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 136
TABLE 78 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 79 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 80 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 138
7.3 MULTIVALENT VACCINES 138
7.3.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET 138
TABLE 81 EXAMPLES OF MULTIVALENT VACCINES 139
TABLE 82 VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 140
TABLE 83 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 140
TABLE 84 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 85 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 86 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 142
8 VACCINES MARKET, BY DISEASE INDICATION 143
8.1 INTRODUCTION 144
TABLE 87 VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 144
8.2 PNEUMOCOCCAL DISEASE 144
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 144
TABLE 88 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 145
TABLE 89 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 146
TABLE 90 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 146
TABLE 91 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147

TABLE 92 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147
TABLE 93 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 148
8.3 INFLUENZA 148
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 148
TABLE 94 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 149
TABLE 95 VACCINES MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD BILLION) 150
TABLE 96 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 150
TABLE 97 EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 98 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 99 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 152
8.4 COMBINATION VACCINES 152
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET 152
TABLE 100 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 153
TABLE 101 VACCINES MARKET FOR COMBINATION VACCINES, BY REGION, 2021–2028 (USD BILLION) 154
TABLE 102 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 154
TABLE 103 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 104 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 105 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 156
8.5 HPV 156
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 156
TABLE 106 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 157
TABLE 107 VACCINES MARKET FOR HPV, BY REGION, 2021–2028 (USD BILLION) 158
TABLE 108 NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 158
TABLE 109 EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 110 ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 111 LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 160
8.6 MENINGOCOCCAL DISEASE 160
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET 160
TABLE 112 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 161
TABLE 113 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 161
TABLE 114 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 115 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
TABLE 117 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
8.7 HERPES ZOSTER 163
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 163
TABLE 118 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021–2028 (USD BILLION) 164
TABLE 119 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 120 EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
TABLE 122 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
8.8 ROTAVIRUS 166
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET 166
TABLE 123 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 167
TABLE 124 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021–2028 (USD BILLION) 167
TABLE 125 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 126 EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 127 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
TABLE 128 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
8.9 MMR 170
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET 170
TABLE 129 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 170
TABLE 130 VACCINES MARKET FOR MMR, BY REGION, 2021–2028 (USD BILLION) 171
TABLE 131 NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 171
TABLE 132 EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 133 ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 134 LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 173
8.10 VARICELLA 173
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET 173
TABLE 135 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 173
TABLE 136 VACCINES MARKET FOR VARICELLA, BY REGION, 2021–2028 (USD BILLION) 174
TABLE 137 NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 174
TABLE 138 EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 139 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 140 LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 176
8.11 HEPATITIS 176
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET 176
TABLE 141 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 177
TABLE 142 VACCINES MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 143 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 144 EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 145 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
TABLE 146 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
8.12 DTP 180
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET 180
TABLE 147 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 180
TABLE 148 VACCINES MARKET FOR DTP, BY REGION, 2021–2028 (USD BILLION) 181
TABLE 149 NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 181
TABLE 150 EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 151 ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 152 LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 183
8.13 POLIO 183
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 183
TABLE 153 VACCINES MARKET FOR POLIO, BY REGION, 2021–2028 (USD BILLION) 184
TABLE 154 NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 155 EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 156 ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
TABLE 157 LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
8.14 OTHER DISEASE INDICATIONS 186
FIGURE 31 NUMBER OF COVID-19 CASES IN US, 2020–2023 187
TABLE 158 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 187
TABLE 159 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD BILLION) 188
TABLE 160 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 188
TABLE 161 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 162 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 163 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 190
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 191
9.1 INTRODUCTION 192
TABLE 164 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 192
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 192
9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET 192
TABLE 165 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 193
TABLE 166 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 194
TABLE 167 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 194
TABLE 168 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 169 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 170 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 196
9.3 ORAL ADMINISTRATION 196
9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET 196
TABLE 171 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 197
TABLE 172 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 197
TABLE 173 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 174 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 175 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 199
9.4 OTHER ROUTES OF ADMINISTRATION 199
TABLE 176 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 200
TABLE 177 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 200
TABLE 178 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 179 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 180 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 202
10 VACCINES MARKET, BY END USER 203
10.1 INTRODUCTION 204
TABLE 181 VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 204
10.2 PEDIATRIC VACCINES 204
10.2.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET 204
TABLE 182 VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021–2028 (USD BILLION) 205
TABLE 183 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 184 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 185 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
TABLE 186 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
10.3 ADULT VACCINES 207
10.3.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD 207
TABLE 187 VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021–2028 (USD BILLION) 209
TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 209
TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 211
11 VACCINES MARKET, BY REGION 212
11.1 INTRODUCTION 213
TABLE 192 VACCINES MARKET, BY REGION, 2021–2028 (USD BILLION) 213
11.2 NORTH AMERICA 213
FIGURE 32 NORTH AMERICA: VACCINES MARKET SNAPSHOT 214
TABLE 193 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 215
TABLE 194 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 215
TABLE 195 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 216
TABLE 196 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 216
TABLE 197 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 217
TABLE 198 NORTH AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 217
11.3 NORTH AMERICA: RECESSION IMPACT 217
11.3.1 US 218
11.3.1.1 US to dominate North American vaccines market during forecast period 218
TABLE 199 US: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 219
TABLE 200 US: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 219
TABLE 201 US: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 220
TABLE 202 US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 220
TABLE 203 US: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 221
11.3.2 CANADA 221
11.3.2.1 High incidence of infectious diseases to drive market 221
TABLE 204 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 222
TABLE 205 CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 222
TABLE 206 CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 223
TABLE 207 CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 223
TABLE 208 CANADA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 224
11.4 EUROPE 224
TABLE 209 EUROPE: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 224
TABLE 210 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 225
TABLE 211 EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 225
TABLE 212 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 226
TABLE 213 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 226
TABLE 214 EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 227
11.5 EUROPE: RECESSION IMPACT 227
11.5.1 GERMANY 227
11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market 227
TABLE 215 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 229
TABLE 216 GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 229
TABLE 217 GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 230
TABLE 218 GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 230
TABLE 219 GERMANY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 231
11.5.2 UK 231
11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market 231
TABLE 220 UK: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 232
TABLE 221 UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 232
TABLE 222 UK: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 233
TABLE 223 UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 233
TABLE 224 UK: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 234
11.5.3 FRANCE 234
11.5.3.1 Favorable government initiatives for mass immunization to drive market 234
TABLE 225 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 235
TABLE 226 FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 235
TABLE 227 FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 236
TABLE 228 FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 236
TABLE 229 FRANCE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 237
11.5.4 ITALY 237
11.5.4.1 Higher investments by companies for increased production capacities to drive market 237
TABLE 230 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 238
TABLE 231 ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 238
TABLE 232 ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 239
TABLE 233 TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 239
TABLE 234 ITALY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 240
11.5.5 SPAIN 240
11.5.5.1 Rising investments in vaccine development by private organizations to drive market 240
TABLE 235 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 241
TABLE 236 SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 241
TABLE 237 SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 242
TABLE 238 SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 242
TABLE 239 SPAIN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 243
11.5.6 REST OF EUROPE 243
TABLE 240 REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 244
TABLE 241 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 244
TABLE 242 REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 245
TABLE 243 REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 245
TABLE 244 REST OF EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 246
11.6 ASIA PACIFIC 246
FIGURE 33 ASIA PACIFIC: VACCINES MARKET SNAPSHOT 247
TABLE 245 ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 248
TABLE 246 ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 248
TABLE 247 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 249
TABLE 248 ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 249
TABLE 249 ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 250
TABLE 250 ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 250
1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 43
1.3 STUDY SCOPE 44
FIGURE 1 AUTOMOTIVE ACTUATORS MARKET SEGMENTATION 44
1.3.1 REGIONS COVERED 45
1.3.2 YEARS CONSIDERED 45
1.4 INCLUSIONS AND EXCLUSIONS 46
TABLE 1 INCLUSIONS AND EXCLUSIONS 46
1.5 CURRENCY CONSIDERED 47
TABLE 2 CURRENCY EXCHANGE RATES 47
1.6 UNIT CONSIDERED 48
1.7 STAKEHOLDERS 48
1.8 SUMMARY OF CHANGES 49
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
FIGURE 2 AUTOMOTIVE ACTUATORS MARKET: RESEARCH DESIGN 50
FIGURE 3 RESEARCH METHODOLOGY MODEL 51
2.1.1 SECONDARY DATA 51
2.1.1.1 Key secondary sources for ICE vehicle production/electric vehicle sales 51
2.1.1.2 Key secondary sources for market sizing 52
2.1.1.3 Key data from secondary sources 52
2.1.2 PRIMARY DATA 53
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 53
2.1.2.1 Sampling techniques and data collection methods 53
2.1.2.2 List of primary participants 54
2.2 MARKET SIZE ESTIMATION 54
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 55
2.2.1 BOTTOM-UP APPROACH 56
FIGURE 6 BOTTOM-UP APPROACH: BY PRODUCT TYPE, ACTUATION, MOTION, AND VEHICLE TYPE AT REGIONAL AND COUNTRY LEVELS 56
2.3 DATA TRIANGULATION 57
FIGURE 7 DATA TRIANGULATION 57
2.3.1 RECESSION IMPACT ANALYSIS 58
2.4 FACTOR ANALYSIS FOR MARKET SIZING: DEMAND AND SUPPLY SIDES 58
2.5 FACTOR ANALYSIS: FACTORS IMPACTING MARKET 59
2.6 RISK ANALYSIS 59
2.7 ASSUMPTIONS 60
2.7.1 RESEARCH ASSUMPTIONS 60
2.7.2 MARKET ASSUMPTIONS 61
2.8 RESEARCH LIMITATIONS 63
3 EXECUTIVE SUMMARY 64
3.1 REPORT SUMMARY 64
FIGURE 8 AUTOMOTIVE ACTUATORS MARKET, BY REGION, 2023 VS. 2030 (USD MILLION) 65

ページTOPに戻る

Table of Contents

Summary

The Automotive Actuators Market is estimated to grow from USD 20.9 billion in 2023 to USD 29.3 billion by 2030 at a CAGR of 4.9% during the forecast period.
Growing luxury car & SUV sales in developed countries, increased production of vehicles equipped with driver assistant features and increased focus on safety with Global NCAP ratings encourage OEMs to focus on developing automotive actuators for various applications.
“Brake Actuators are dominating the automotive actuators market.”
The brake actuators segment is projected to dominate the automotive actuators market due to its mandatory fitment in all types of vehicle segments and the high cost of these actuators compared to other types. The usual number of brake actuators is 4 in passenger cars, and light commercial vehicles installed one unit per wheel. Improving the safety and convenience of passenger vehicles is the prime focus of government bodies and OEMs worldwide. Due to this, stringent safety regulations have been implemented in different locations. Due to this, advanced brake technologies such as Anti-lock braking system (ABS), Electronic Brakeforce Distribution (EBD), Brake Assist, etc. are becoming mandatory in most countries.
Further, the European Union mandated the installation of emergency braking systems in passenger cars and LCVs to prevent mishaps, a part of ADAS technology. Additionally, advancements are taking place in brake technologies, such as brake-by-wire systems and regenerative braking systems, which improve the performance and safety of braking systems and the fuel efficiency of vehicles. These factors, regulations, and some additional safety features are attributed to the growth of the efficient brake actuators segment in the upcoming years.
Alternatively, the average count for brake actuators in heavy commercial vehicles is much higher and costlier. The heavy commercial vehicles’ air disc brake systems are getting increasingly popular due to their better stopping capabilities. This will prompt the manufacturers to offer innovative solutions with brake actuators in every size and performance level, like brake actuators for air disc brakes and drum brakes, which will drive the automotive actuators market.

“Passenger cars is the largest as well as fastest growing on-highway vehicles segment in the automotive actuators market.”
The passenger car segment is estimated to be the most promising and fastest market for automotive actuators. The growth is mainly attributed to the highest share of the passenger cars segment, with more than 70% in overall vehicle production. The growing adoption of mechanical and electronic components propels the automotive car actuators market. Passenger vehicles are equipped with some standard actuators that are mandatorily installed, such as throttle body, engine cooling valve, brake, air conditioning, and power windows across all categories. Further, the shifting trends towards engine downsizing and GDI engines will prompt the demand for turbo and exhaust gas recirculation (EGR) system actuators.
Further, developed countries of Europe, North America, and Asian countries such as Japan and South Korea, with higher disposal income and strong demand for mid-range, premium, and full-size SUVs, incline comfort and luxury features. This will drive the demand for advanced features such as powered seats, multi-zone air conditioning, 2nd and 3rd-row air conditioning, electric tailgate, door locks, active grille shutters, and passive and active cabin ventilation will strive to adopt automotive actuators for these applications in passenger cars segment. Further, government initiatives such as the European New Car Assessment Program (Euro NCAP) and Vision Zero have compelled OEMs in Europe and other developing countries of Asia, such as China and India, to follow European norms to include advanced safety features, which will likely to boost the demand of automotive actuators in the passenger cars segment.

“Asia Pacific is the prominent region in the automotive actuators market.”
Asia Pacific is the most prominent automotive actuators market and is expected to grow at the fastest CAGR during the forecast period. The Asia Pacific region has emerged as a hub for automotive production in recent years and holds the largest share in global vehicle production, with more than 55% in 2022. The considerable vehicle production in the region offers a tremendous growth opportunity for the automotive actuators market. Also, growing demand for premium and luxury cars and increasing sales of electric vehicles in countries like China, India, and Japan are propelling the growth of automotive actuators. Also, premium heavy-duty vehicles with superior cabin comfort have spurred the demand for automotive actuators like power seat actuators, power window actuators, brake actuators, and steering column adjustment actuators. In the Asia Pacific region, brake actuators account for the largest market share due to the largest share of passenger cars compared to other regions.
In contrast, telescopic actuators are expected to grow with the highest CAGR owing to their application in various systems of automotive vehicles, such as steering systems, headlight actuation systems, truck lid actuation, etc. Also, the increasing sales of light and heavy commercial vehicles are driving the telescopic actuators market with the highest CAGR owing to its application in various systems of automotive vehicles such as steering systems, headlight actuation systems, truck lid actuation, etc. Many global manufacturers of actuators have a strong presence in the Asia Pacific region, such as Robert Bosch, HELLA GmbH, Brakes India Pvt. Ltd., .

The break-up of the profile of primary participants in the automotive actuators market:
By Companies: Actuators Manufacturers - 30%, Tier 2 Suppliers - 50%, OEMs - 20%
By Designation: C-Level Executives - 60%, Directors- 15%, Others - 25%
By Region: North America - 10%, Asia Pacific - 75%, Europe - 10% and RoW – 5%

Global players dominate the Automotive Actuators Market and comprise several regional players. The key players in the automotive actuators market are Robert Bosch (Germany), HELLA GmbH & Co. KGaA (Germany), Johnson Electric (China), Denso Corporation (Japan), and Continental AG (Germany).

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall Automotive Actuators market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing demand for advanced featured vehicles and Increasing demand for premium vehicles), restraints (declining share of diesel passenger cars), opportunities (Increasing adoption of electric actuators), and challenges (weight and cost reduction) influencing the growth of the Automotive Actuators Market.
• Product Development/Innovation: Detailed insights on upcoming technologies and new product & service launches in the Automotive Actuators market.
• Market Development: Comprehensive market information – the report analyses the authentication and brand protection market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in Automotive Actuators Market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Robert Bosch (Germany), HELLA GmbH & Co. KGaA (Germany), JOHNSON Electric (China), Denso Corporation (Japan), and Continental AG (Germany) among others in Automotive Actuators Market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（ADAS）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（actuators）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（ADAS）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（actuators）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?